83 results
8-K
EX-99.1
SRZN
Surrozen Inc
8 May 24
Surrozen Provides First Quarter 2024 Financial Results and Business Update
4:12pm
with chronic liver disease and healthy volunteers. SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of
target
424B5
SRZN
Surrozen Inc
25 Apr 24
Prospectus supplement for primary offering
4:28pm
SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee … to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for us to advance to a higher dose cohort
8-K
0xyat80vfblp
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.4
ibm0qu 5s
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.1
c87deh74 fx
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
92gzyc3pg826tel3iy1
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
8-K
EX-99.2
vpzw4n
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
8-K
EX-99.1
d0euaaykzsqbi73ulvge
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
424B3
64vp68ky
22 Jan 24
Prospectus supplement
5:24pm
8-K
xu7oor71vrkqlq319owi
18 Jan 24
Other Events
8:41am
424B3
nv3i7b7dksq7ytfxz
8 Nov 23
Prospectus supplement
4:27pm
8-K
EX-3.1
dgnyw1pmayen
13 Oct 23
Amendments to Articles of Incorporation or Bylaws
4:19pm
424B3
pf1kyd wqwrto95
9 Aug 23
Prospectus supplement
4:39pm